Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Revenue from contract with customers (Details)

v3.10.0.1
Summary of Significant Accounting Policies - Revenue from contract with customers (Details)
£ in Millions
1 Months Ended 3 Months Ended 9 Months Ended 13 Months Ended 53 Months Ended
Sep. 30, 2018
USD ($)
Sep. 30, 2017
GBP (£)
Sep. 30, 2017
USD ($)
Jun. 30, 2014
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Milestone
contract
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2018
USD ($)
Collaboration and License Agreement                    
Revenue         $ 40,792,000 $ 27,185,000 $ 58,026,000 $ 33,563,000    
PRAME program                    
Collaboration and License Agreement                    
Number of small-dollar development milestone | Milestone             1      
GlaxoSmithKline Intellectual Property Development Ltd | Collaboration and License Agreement                    
Collaboration and License Agreement                    
Number of contracts with customers | contract             1      
Option Exercise Fee, received   £ 20 $ 26,600,000              
Upfront payment received       $ 42,123,000            
Amount of development milestone achieved                   $ 66,404,000
Estimate of variable consideration             $ 0      
License revenue                    
Collaboration and License Agreement                    
Revenue         $ 39,114,000   $ 39,114,000      
License revenue | GlaxoSmithKline Intellectual Property Development Ltd | Collaboration and License Agreement                    
Collaboration and License Agreement                    
Revenue $ 13,175,000   $ 26,610,000           $ 39,785,000